Amarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013 Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013
Amarin Announces U.S. Patent 8,324,195 Issuance for Vascepa(R) Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces U.S. Patent 8,324,195 Issuance for Vascepa(R)
Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic Alternatives Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic Alternatives
Amarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier
David Stack Appointed to Amarin Board of Directors Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about David Stack Appointed to Amarin Board of Directors
Amarin Announces Notification of Patent Allowance for U.S. Application 13/623,450 Related to Vascepa(R) and FDA Approved MARINE Indication Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Notification of Patent Allowance for U.S. Application 13/623,450 Related to Vascepa(R) and FDA Approved MARINE Indication
Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin
Amarin Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
Amarin Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Submission of a Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
Amarin to Present at the 31st Annual J.P. Morgan Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at the 31st Annual J.P. Morgan Healthcare Conference
